# US 2020/0392491 A1 · Method of Preparing Oligonucleotide Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392491 A1
- Document ID: US20200392491A1
- Status: Published application
- Kind: A1
- Application number: 16/634,078
- Filed: 2018-07-26
- Published: 2020-12-17
- Earliest claimed: 2017-07-28
- Assignees: Nogra Pharma Limited
- Applicants: Nogra Pharma Limited
- Inventors: Anthony Frank; Kevin Klopfer; Donald Joseph Gallagher, Jr.; Laleh Jafarpour
- Web page: https://patentgrep.com/patent/US20200392491A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/3341: 5-Methylcytosine
- C12N 2330/00: Production
- C12N 2330/30: chemically synthesised
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to compositions comprising oligonucleotides, specifically SMAD7 antisense oligonucleotides, and methods for preparing the same.

## Claims

### Claim 1

A single batch composition of an oligonucleotide comprising at least 700 mmol of the oligonucleotide and at most 25 wt. % water; wherein the oligonucleotide has a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 2

A single batch composition of an oligonucleotide comprising at least 2 g/mmol of an at least 700 mmol synthesis scale of the oligonucleotide and at most 25 wt. % water; wherein the oligonucleotide has a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 3

A single batch composition of an oligonucleotide comprising at least 2 kg of the oligonucleotide and at most 25 wt. % water; wherein the oligonucleotide has a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 4

A single batch composition of an oligonucleotide comprising at least 50 mol % of the oligonucleotide output from at least one 700 mmol or greater oligonucleotide synthesis column and at most 25 wt. % water; wherein the oligonucleotide has a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 5 (depends on 1, 2, 3, 4)

The single batch oligonucleotide composition of any one of claims 1-4, wherein at least one of the internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The single batch oligonucleotide composition of any one of claims 1-5, wherein all of the internucleotide linkages of the oligonucleotide are O,O-linked phosphorothioates.

### Claim 7

A substantially pure oligonucleotide composition of an oligonucleotide wherein the 5′-hydroxyl group of the 5′-terminal nucleoside is protected; wherein the oligonucleotide has a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 8 (depends on 7)

The substantially pure oligonucleotide composition of claim 7, wherein only the 5′-hydroxyl group of the 5′-terminal nucleoside is protected.

### Claim 9 (depends on 8)

The substantially pure oligonucleotide composition of claim 8, wherein the protected oligonucleotide is obtained after cleavage and elution from a synthesis column.

### Claim 10 (depends on 7, 8, 9)

The substantially pure oligonucleotide composition of any one of claims 7-9, wherein the degree of purity of the composition is 60% or greater.

### Claim 11 (depends on 7, 8, 9, 10)

The substantially pure oligonucleotide composition of any one of claims 7-10, wherein at least one of the internucleotide linkages of the oligonucleotide is an O,O-linked phosphorothioate.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The substantially pure oligonucleotide composition of any one of claims 7-11, wherein all of the internucleotide linkages of the oligonucleotide are O,O-linked phosphorothioates.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The single batch oligonucleotide composition of any one of claims 1-6 or the substantially pure oligonucleotide composition of any one of claims 7-12, wherein the oligonucleotide is prepared according to a method comprising:
a) providing a linker attached to a solid support wherein the linker comprises a protected hydroxyl group;
b) deprotecting the protected hydroxyl group of the linker thereby creating a deprotected hydroxyl group;
c) independently providing a nucleoside phosphoramidite, wherein the nucleoside phosphoramidite comprises a protected hydroxyl group and a protected phosphoramidite;
d) independently coupling the nucleoside phosphoramidite to the deprotected hydroxyl group of the linker, or to the deprotected hydroxyl group of the nucleoside from the previous iteration of the reaction cycle, thereby creating a phosphite triester linked nucleoside;
e) independently thiolating the protected phosphite triester linkage thereby creating a protected phosphorothioate linkage;
f) optionally, independently capping unreacted deprotected hydroxyl groups;
g) optionally, independently deprotecting the protected hydroxyl group of the nucleoside;
h) repeating the providing, coupling, thiolating, capping, and deprotecting steps (steps c) through g)) a predetermined number of times to provide a solid support-bound oligonucleotide;
i) deprotecting the protected phosphorothioate linkages;
j) cleaving the oligonucleotide from the solid support;
k) eluting the oligonucleotide from the solid support;
l) purifying the oligonucleotide eluate using an ion exchange chromatography column; and
m) concentrating the solution of the oligonucleotide compound with thin film evaporation.

### Claim 14 (depends on 13)

The oligonucleotide composition of claim 13, wherein the purifying step 1) comprises:
1) loading the oligonucleotide eluate from eluting step k) onto the ion exchange chromatography column;
2) deprotecting the protected hydroxyl group from the terminal nucleoside; and
3) eluting the oligonucleotide from the ion exchange chromatography column using a salt gradient.

### Claim 15 (depends on 13)

The oligonucleotide composition of claim 13, wherein the purifying step 1) comprises:
1) loading the oligonucleotide eluate from eluting step k) onto the ion exchange chromatography column;
2) deprotecting the protected hydroxyl group from the terminal nucleoside;
3) eluting the oligonucleotide from the ion exchange chromatography column using a salt gradient; and
4) desalting the oligonucleotide eluate from the ion exchange column via ultrafiltration and/or diafiltration.

### Claim 16 (depends on 13, 14, 15)

The oligonucleotide composition of any one of claims 13-15, wherein the solid support having a linker attached thereto is a crosslinked polystyrene.

### Claim 17 (depends on 13, 14, 15, 16)

The oligonucleotide composition of any one of claims 13-16, wherein the unreacted deprotected hydroxyl groups are capped with an acyl group.

### Claim 18 (depends on 13, 14, 15, 16, 17)

The oligonucleotide composition of any one of claims 13-17, wherein the capping of the unreacted deprotected hydroxyl groups comprises adding:
a) a first capping solution (Cap A), comprising N-methylimidazole (NMI), pyridine, and acetonitrile; and
b) a second capping solution (Cap B), comprising capping agent and acetonitrile.

### Claim 19 (depends on 18)

The oligonucleotide composition of claim 18, wherein the capping agent is isobutyric anhydride.

### Claim 20 (depends on 13, 14, 15, 16, 17, 18, 19)

The oligonucleotide composition of any one of claims 13-19, wherein the thiolating agent is xanthane hydride (XH).

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19, 20)

The oligonucleotide composition of any one of claims 13-20, wherein the cleaving of the deprotected solid support-bound oligonucleotide comprises providing a solution of ammonium hydroxide.

### Claim 22 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21)

The oligonucleotide composition of any one of claims 13-21, wherein the ion exchange chromatography is an anion exchange chromatography.

### Claim 23 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The oligonucleotide composition of any one of claims 13-22, wherein the oligonucleotide eluate is loaded onto the ion exchange chromatography column with a basic aqueous solution.

### Claim 24 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The oligonucleotide composition of any one of claims 13-23, wherein the 5′-hydroxyl protected group of the loaded oligonucleotide eluate on the ion exchange chromatography column is deprotected with 80% aqueous acetic acid.

### Claim 25 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The oligonucleotide composition of any one of claims 13-24, wherein the fully deprotected oligonucleotide is eluted from the ion exchange chromatography column with a basic salt gradient.

### Claim 26 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The oligonucleotide composition of any one of claims 13-25, wherein the fully deprotected oligonucleotide is desalted via an ultrafiltration and/or diafiltration process.

### Claim 27 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The oligonucleotide composition of any one of claims 13-26, wherein the ultrafiltration and/or diafiltration process utilizes water at a pH in the range of 5-8.

### Claim 28 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The oligonucleotide composition of any one of claims 13-27, wherein the fully deprotected oligonucleotide eluate is concentrated with thin film evaporation.

### Claim 29 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The oligonucleotide composition of any one of claims 13-28, wherein the method steps are performed in the order in which they are recited.

### Claim 30 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The oligonucleotide composition of any one of claims 13-29, wherein the optional step of capping the unreacted deprotected hydroxyl groups and the optional step of deprotecting the protected hydroxyl group of the nucleoside are performed in each iteration of the reaction cycle, exclusive of the last iteration.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition, comprising at least a portion of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, with a pharmaceutically acceptable adjuvant and/or excipient.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is an oral dosage form.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the oral dosage form of the pharmaceutical composition is a tablet.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the tablet is a coated tablet.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The pharmaceutical composition of any one of claims 31-34, wherein the at least a portion of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, comprises in the range of between 10-500 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The pharmaceutical composition of any one of claims 31-35, wherein the at least a portion of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, comprises about 40 mg or about 160 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 37 (depends on 31, 32, 33, 34, 35, 36)

A method of treating or managing inflammatory bowel disease (IBD) in a patient having IBD, comprising administering the pharmaceutical composition of any one of claims 31-36.

### Claim 38 (depends on 37)

The method of treating of claim 37, wherein the inflammatory bowel disease (IBD) is Crohn's disease (CD).

### Claim 39 (depends on 37)

The method of treating of claim 37, wherein the inflammatory bowel disease (IBD) is ulcerative colitis (UC).

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A method of preparing the pharmaceutical composition of any one of claims 31-36, comprising formulating the at least a portion of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, with the pharmaceutically acceptable adjuvant and/or excipient.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A method of preparing a series of tablets, comprising partitioning the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, into a series of portions, amounts, or doses, suitable for oral dosage, and combining each portion, amount, or dose, suitable for oral dosage, of the series of portions amounts, or doses, suitable for oral dosage, with a pharmaceutically acceptable adjuvant and/or excipient.

### Claim 42 (depends on 41)

The method of preparing the series of tablets of claim 41, wherein the series of tablets is at least 100 tablets.

### Claim 43 (depends on 41)

The method of preparing the series of tablets of claim 41, wherein the series of tablets is between 100-1,000,000 tablets.

### Claim 44 (depends on 41, 42, 43)

The method of preparing the series of tablets of any one of claims 41-43, wherein the series of tablets is a series of coated tablets.

### Claim 45 (depends on 41, 42, 43, 44)

The method of preparing the series of tablets of any one of claims 41-44, wherein each portion, amount, or dose, suitable for oral dosage, of the series of portions, amounts, or doses, suitable for oral dosage, comprises in the range of between 10-500 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The method of preparing the series of tablets of any one of claims 41-45, wherein each portion, amount, or dose, suitable for oral dosage, of the series of portions, amounts, or doses, suitable for oral dosage, comprises about 40 mg or about 160 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A pharmaceutical composition batch, comprising at least a portion of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30, and a pharmaceutically acceptable adjuvant and/or excipient.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 47)

The pharmaceutical batch composition of claim 47, wherein the pharmaceutical composition batch comprises at least 10 wt. %, at least 20 wt. %, at least 30 wt. %, at least 40 wt. %, at least 50 wt. %, at least 60 wt. %, at least 70 wt. %, at least 80 wt. %, at least 90 wt. %, at least 95 wt. %, or 100 wt. %, of the single batch oligonucleotide composition of any one of claims 1-6, the substantially pure oligonucleotide composition of any one of claims 7-12, or the oligonucleotide composition of any one of claims 13-30.

### Claim 49 (depends on 48)

The pharmaceutical batch composition of claim 48 or 48, wherein the pharmaceutical composition batch comprises at least one tablet or at least one coated tablet.

### Claim 50 (depends on 48)

The pharmaceutical batch composition of claim 48 or 48, wherein the pharmaceutical composition batch comprises a series of tablets.

### Claim 51 (depends on 50)

The pharmaceutical batch composition of claim 50, wherein the series of tablets is at least 100 tablets.

### Claim 52 (depends on 50)

The pharmaceutical batch composition of claim 50, wherein the series of tablets is between 100-1,000,000 tablets.

### Claim 53 (depends on 50, 51, 52)

The pharmaceutical batch composition of any one of claims 50-52, wherein the series of tablets is a series of coated tablets.

### Claim 54 (depends on 47, 48, 49, 50, 51, 52, 53)

The pharmaceutical batch composition of any one of claims 47-53, wherein the at least one tablet, the at least one coated tablet, each of the series of tablets, or each of the series of coated tablets, comprises in the range of between 10-500 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.

### Claim 55 (depends on 47, 48, 49, 50, 51, 52, 53, 54)

The pharmaceutical batch composition of any one of claims 47-54, wherein the at least one tablet, the at least one coated tablet, each of the series of tablets, or each of the series of coated tablets, comprises about 40 mg or 160 mg of the oligonucleotide having a nucleic acid sequence:
SEQ ID NO: 3:
(5′-GTX GCC CCT TCT CCC XGC AGC-3′),
wherein X represents 5-methyl-2′-deoxycytidine.
